BLGO BIOLARGO, INC.

CIK 0000880242 18 ready 8-Ks latest May 6, 2026, 7:59 PM ET RSS · JSON

Activity: NORMAL 2 filings / 30d vs 1 baseline

Ready 8-Ks 18

Latest filing May 6, 2026, 7:59 PM ET

Top materiality 0.80

Event mix other_material ×10 · other ×4 · earnings ×4

Sentiment 3 pos · 2 neg · 13 neu

Recent 8-K filings for BLGO

Highest-materiality recent filing

BioLargo revokes Pooph license due to $3.8M default; expects substantial impairment of $3.49M note receivable

September 25, 2025, 7:59 PM ET other material materiality 0.80 negative item 1.02 item 2.06 item 7.01 item 9.01

Pooph owed BioLargo approximately $3.8M in past-due royalties and product invoices; BioLargo revoked license on Sept 24, 2025.
BioLargo expects substantial impairment of its $3.486M note receivable from Pooph on its June 30 balance sheet.

Read filing →

May 6, 2026, 7:59 PM ET other materiality 0.15 neutral item 7.01 item 9.01

BioLargo CEO holds Discord town hall; transcript filed as 8-K

CEO Dennis Calvert participated in a May 5, 2026 town hall on Discord; transcript and investor summary furnished.
May 4, 2026, 7:59 PM ET other materiality 0.20 neutral item 7.01 item 9.01

BioLargo CEO to host town hall on Discord May 5; transcript to follow

Town hall on May 5, 2026 at 1:00 PM PT hosted on BioLargo Shareholder Discord channel.
March 25, 2026, 7:59 PM ET other material materiality 0.60 neutral item 1.01 item 3.02 item 9.01 ◈ Material Agreements

BioLargo enters $10M equity purchase agreement with Clearthink Capital Partners

Clearthink commits to buy up to $10M of BioLargo common stock over 36 months under a Strata purchase agreement.
March 5, 2026, 6:59 PM ET earnings materiality 0.70 negative item 7.01 item 9.01

BioLargo 2025 revenue falls 56% to $7.8M; net loss widens to $15.2M

Total revenue dropped to $7.8M from $17.8M in 2024 due to termination of largest customer's license.
November 18, 2025, 6:59 PM ET other material materiality 0.50 neutral item 8.01 item 9.01

BioLargo issues 624,383 shares to officers for salary; locked until $40M revenue or $300M cap

Two officers converted $99,901 of unpaid salary/expenses into 624,383 shares at $0.16/share.
November 14, 2025, 6:59 PM ET other material materiality 0.25 neutral item 7.01 item 9.01

BioLargo to present investor webcast on Nov 14, 2025 with slides attached

Investor webcast scheduled for Nov 14, 2025 at 1:30 PM PT.
October 20, 2025, 7:59 PM ET other materiality 0.15 neutral item 7.01 item 9.01

BioLargo presents at LD Micro Main Event; no material new information disclosed

Company presented slides at LD Micro Main Event on October 20, 2025 in San Diego.
September 25, 2025, 7:59 PM ET other material materiality 0.80 negative item 1.02 item 2.06 item 7.01 item 9.01

BioLargo revokes Pooph license due to $3.8M default; expects substantial impairment of $3.49M note receivable

Pooph owed BioLargo approximately $3.8M in past-due royalties and product invoices; BioLargo revoked license on Sept 24, 2025.
August 15, 2025, 7:59 PM ET other material materiality 0.15 neutral item 7.01 item 9.01

BioLargo presents slides at investor conference; no material new details in filing

Slides were presented at a webcast investor conference on August 15, 2025 at 8:00 AM PT.
July 23, 2025, 7:59 PM ET other material materiality 0.75 neutral item 7.01 item 9.01

BioLargo mid-year update: Clyra distribution deals, Cellinity MOUs, PFAS project; Pooph sales drag

Clyra Medical secured distribution agreements covering 6,100 hospitals, 6,300 ASCs, 2,200 wound care clinics; raised $3.3M in new capital.
June 25, 2025, 7:59 PM ET other material materiality 0.55 neutral item 5.07 item 7.01 item 9.01

BioLargo shareholders approve reverse split authorization; board has no immediate plans

All seven director nominees elected, including Dennis Calvert, Kenneth Code, Linda Park.
May 15, 2025, 7:59 PM ET other material materiality 0.20 neutral item 7.01 item 9.01

BioLargo presents at investor webcast; no financial details in filing

Slide deck presented at webcast investor conference on May 15, 2025 at 1:30 PM PT.
March 31, 2025, 7:59 PM ET earnings materiality 0.65 positive item 7.01 item 9.01

BioLargo reports record 2024 revenues of $17.8M, up 45% YoY; net loss narrows 6%

Revenue $17.779M, up 45% from 2023; tenth consecutive year of revenue growth.
November 15, 2024, 6:59 PM ET earnings materiality 0.65 positive item 7.01 item 9.01

BioLargo Q3: YTD revenue up 80% to $14.1M; net loss narrows

Year-to-date revenue $14.1M, up 80% YoY; Q3 revenue $4.4M, up 63% YoY.
August 15, 2024, 7:59 PM ET other materiality 0.05 neutral item 7.01 item 9.01

BioLargo files slide deck from May 2024 conference; no new material data

Presentation from a May 14, 2024 investor webcast is now filed on Form 8-K.
June 20, 2024, 7:59 PM ET other material materiality 0.15 neutral item 5.07 item 9.01

BioLargo shareholders elect all seven directors, approve executive compensation, auditor, and 2024 equity plan

All seven director nominees elected: Dennis Calvert, Kenneth Code, Dennis Marshall, Joseph Provenzano, Jack Strommen, Linda Park, Christina Bray.
June 13, 2024, 7:59 PM ET other material materiality 0.10 neutral item 7.01 item 9.01

BioLargo presents slides at annual meeting; no extractable data

Annual stockholder meeting held June 13, 2024; presentation slides furnished.
May 15, 2024, 7:59 PM ET earnings materiality 0.65 positive item 7.01 item 9.01

BioLargo reports record Q1 revenue, positive operating cash flow of $481K

Q1 2024 revenue $4.76M, up 28% YoY and 9% QoQ; generated $481K positive operating cash flow.

Materiality & sentiment trend

Max materiality 0.80 · Median 0.38 · Most common event other_material

3 positive 2 negative 13 neutral

source · BLGO on sec.gov